Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $85 | In Stock | |
5 mg | $248 | In Stock | |
10 mg | $372 | In Stock | |
25 mg | $626 | In Stock | |
50 mg | $892 | In Stock | |
100 mg | $1,220 | In Stock |
Description | RAGE antagonist peptide acetate is an advanced antagonist of glycation end products (RAGE). RAGE antagonist peptide acetate possesses anti-tumor and anti-inflammatory activities. RAGE antagonist peptide acetate prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. |
In vitro | In cancer cells, RAGE antagonist peptide acetate reduces the ability of the ligands to stimulate RAGE activation of NFκB[2]. |
In vivo | In mice bearing asthma, RAGE antagonist peptide acetate (RAP; 4 mg/kg; i.p.) blunts airway reactivity, airway inflammation and goblet cell metaplasia, and decreases release of Th2 cytokines. RAGE antagonist peptide acetate also reduces total, cytoplasmic and nuclear levels of β-catenin, enhanced β-catenin phosphorylation at Ser33/37/Thr41, which triggers ubiquitination, down-regulated expression of β-catenin targeted genes, and tends to keep β-catenin at the cytomembrane, shifting β-catenin from a signalling active pattern to an adhesive function[1]. RAGE antagonist peptide acetate reduces the growth and metastasis of pancreatic tumors and also inhibited glioma tumor growth. RAGE antagonist peptide acetate (100 μg) inhibits RAGE-mediated Basal NFκB Activity in PDAC cells in vivo[2]. |
Molecular Weight | 1332.61 |
Formula | C59H105N13O19S |
Cas No. |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.